BAUSCH HEALTH COS INC (BHC) Fundamental Analysis & Valuation
NYSE:BHC • CA0717341071
Current stock price
5.58 USD
-0.05 (-0.89%)
At close:
5.6 USD
+0.02 (+0.36%)
After Hours:
This BHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BHC Profitability Analysis
1.1 Basic Checks
- BHC had positive earnings in the past year.
- BHC had a positive operating cash flow in the past year.
- In the past 5 years BHC reported 4 times negative net income.
- BHC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- The Return On Assets of BHC (0.60%) is better than 80.63% of its industry peers.
- BHC has a Return On Invested Capital of 7.78%. This is amongst the best in the industry. BHC outperforms 86.39% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BHC is significantly below the industry average of 13.10%.
- The last Return On Invested Capital (7.78%) for BHC is above the 3 year average (6.89%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- The Profit Margin of BHC (1.53%) is better than 80.63% of its industry peers.
- Looking at the Operating Margin, with a value of 21.28%, BHC belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
- BHC's Operating Margin has improved in the last couple of years.
- BHC's Gross Margin of 70.65% is fine compared to the rest of the industry. BHC outperforms 77.49% of its industry peers.
- BHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. BHC Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BHC is creating some value.
- The number of shares outstanding for BHC has been increased compared to 1 year ago.
- The number of shares outstanding for BHC has been increased compared to 5 years ago.
- Compared to 1 year ago, BHC has an improved debt to assets ratio.
2.2 Solvency
- BHC has an Altman-Z score of 0.29. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of BHC (0.29) is comparable to the rest of the industry.
- The Debt to FCF ratio of BHC is 21.00, which is on the high side as it means it would take BHC, 21.00 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 21.00, BHC is doing good in the industry, outperforming 75.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.29 |
ROIC/WACC1.19
WACC6.54%
2.3 Liquidity
- A Current Ratio of 1.47 indicates that BHC should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.47, BHC is doing worse than 76.44% of the companies in the same industry.
- A Quick Ratio of 1.08 indicates that BHC should not have too much problems paying its short term obligations.
- BHC has a worse Quick ratio (1.08) than 79.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. BHC Growth Analysis
3.1 Past
- BHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- The Earnings Per Share has been decreasing by -1.13% on average over the past years.
- The Revenue has been growing slightly by 6.66% in the past year.
- Measured over the past years, BHC shows a small growth in Revenue. The Revenue has been growing by 5.04% on average per year.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- Based on estimates for the next years, BHC will show a decrease in Earnings Per Share. The EPS will decrease by -1.04% on average per year.
- The Revenue is expected to decrease by -0.80% on average over the next years.
EPS Next Y21.76%
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
EPS Next 5Y-1.04%
Revenue Next Year4.48%
Revenue Next 2Y2.16%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.8%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. BHC Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 1.48 indicates a rather cheap valuation of BHC.
- Based on the Price/Earnings ratio, BHC is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
- BHC's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.35.
- Based on the Price/Forward Earnings ratio of 1.22, the valuation of BHC can be described as very cheap.
- BHC's Price/Forward Earnings ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.23. BHC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.48 | ||
| Fwd PE | 1.22 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BHC is valued cheaper than 95.81% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BHC is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.1 | ||
| EV/EBITDA | 6.38 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of BHC may justify a higher PE ratio.
- A cheap valuation may be justified as BHC's earnings are expected to decrease with -5.25% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
5. BHC Dividend Analysis
5.1 Amount
- No dividends for BHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BHC Fundamentals: All Metrics, Ratios and Statistics
5.58
-0.05 (-0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners44.98%
Inst Owner Change0.1%
Ins Owners11.09%
Ins Owner Change10.2%
Market Cap2.08B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.39 (32.44%)
Short Float %1.85%
Short Ratio2.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)-0.47%
PT rev (3m)0.57%
EPS NQ rev (1m)-0.72%
EPS NQ rev (3m)-7.05%
EPS NY rev (1m)5.29%
EPS NY rev (3m)7.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.02%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.48 | ||
| Fwd PE | 1.22 | ||
| P/S | 0.2 | ||
| P/FCF | 2.1 | ||
| P/OCF | 1.49 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.38 |
EPS(TTM)3.77
EY67.56%
EPS(NY)4.59
Fwd EY82.27%
FCF(TTM)2.66
FCFY47.65%
OCF(TTM)3.75
OCFY67.18%
SpS27.49
BVpS-1.48
TBVpS-44.1
PEG (NY)0.07
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.29 |
F-Score6
WACC6.54%
ROIC/WACC1.19
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y21.76%
EPS Next 2Y6.99%
EPS Next 3Y-5.25%
EPS Next 5Y-1.04%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.48%
Revenue Next 2Y2.16%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.8%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year34.28%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.3%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
What is the valuation status of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
What is the profitability of BHC stock?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
How financially healthy is BAUSCH HEALTH COS INC?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.
What is the earnings growth outlook for BAUSCH HEALTH COS INC?
The Earnings per Share (EPS) of BAUSCH HEALTH COS INC (BHC) is expected to grow by 21.76% in the next year.